[go: up one dir, main page]

MX2019003908A - Metodo por multiproteasa. - Google Patents

Metodo por multiproteasa.

Info

Publication number
MX2019003908A
MX2019003908A MX2019003908A MX2019003908A MX2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A MX 2019003908 A MX2019003908 A MX 2019003908A
Authority
MX
Mexico
Prior art keywords
methods
protease
proteases
protein
combination
Prior art date
Application number
MX2019003908A
Other languages
English (en)
Inventor
Trkulja Carolina
Orwar Owe
Davidson Max
Hägglund Jessica
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019003908A publication Critical patent/MX2019003908A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a métodos para identificar un epítope en una proteína que se puede unir por un anticuerpo. Los métodos de la invención normalmente implican una etapa de proteólisis limitada o restringida de una proteína utilizando una única primera proteasa o una combinación de primeras proteasas, y una etapa de proteólisis adicional mediante el uso de una única segunda proteasa o una combinación de segundas proteasas. La invención también se refiere a epítopes identificados y a anticuerpos que se unen a epítopes que han sido identificados mediante los métodos de la invención.
MX2019003908A 2016-10-06 2017-10-06 Metodo por multiproteasa. MX2019003908A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1617002.9A GB201617002D0 (en) 2016-10-06 2016-10-06 Multi-protease method
PCT/EP2017/075532 WO2018065599A1 (en) 2016-10-06 2017-10-06 Multi-protease method

Publications (1)

Publication Number Publication Date
MX2019003908A true MX2019003908A (es) 2019-06-10

Family

ID=57610568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003908A MX2019003908A (es) 2016-10-06 2017-10-06 Metodo por multiproteasa.

Country Status (15)

Country Link
US (1) US11408883B2 (es)
EP (1) EP3523659B1 (es)
JP (1) JP7046931B2 (es)
KR (1) KR102411384B1 (es)
CN (1) CN109891247B (es)
AU (1) AU2017339096B2 (es)
BR (1) BR112019006624A2 (es)
CA (1) CA3039064A1 (es)
ES (1) ES2994658T3 (es)
GB (1) GB201617002D0 (es)
IL (1) IL265612B2 (es)
MA (1) MA46454A (es)
MX (1) MX2019003908A (es)
NZ (1) NZ752437A (es)
WO (1) WO2018065599A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41842A (fr) 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope
GB201918103D0 (en) * 2019-12-10 2020-01-22 Oblique Therapeutics Ab Epitopes and antibodies
CN113501869A (zh) * 2020-03-23 2021-10-15 浙江京新药业股份有限公司 具有创面修复作用的肽
CN114853855B (zh) * 2022-04-14 2023-06-20 安徽省华信生物药业股份有限公司 一种具有促降血糖激素glp-1分泌作用的富铬酵母活性肽

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281404A3 (en) 1990-10-18 2004-04-07 Cancerforskningsfonden af 1989 (fonden til fremme af eksperimentel cancerforskning) Use of antibodies against the urokinase receptor
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
US7939295B2 (en) 2001-07-13 2011-05-10 Merck Patent Gmbh Methods for reducing immunogenicity of polypeptides
US7632686B2 (en) 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
WO2004031730A2 (en) * 2002-10-03 2004-04-15 Norman Leigh Anderson High sensitivity quantitation of peptides by mass spectrometry
TWI385180B (zh) * 2003-07-15 2013-02-11 安美基公司 作為選擇性神經生長因子(ngf)通道抑制劑之人類抗-ngf中和抗體
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
WO2006005472A1 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with vanilloid receptor 1 (vr1)
US20060292639A1 (en) 2004-08-13 2006-12-28 Adolor Corporation Splice variant of the vanilloid receptor VR1A
WO2006047417A2 (en) 2004-10-21 2006-05-04 University Of Florida Research Foundation, Inc. Detection of cannabinoid receptor biomarkers and uses thereof
SE0403139D0 (sv) 2004-12-23 2004-12-23 Nanoxis Ab Device and use thereof
JP2008175814A (ja) 2006-12-21 2008-07-31 Eisai R & D Management Co Ltd 尿中タンパク質分子の検出・定量による糖尿病性腎症の検査方法及びそれに使用するキット
WO2008120684A1 (ja) 2007-03-30 2008-10-09 Yamaguchi University 急性中枢神経障害の予後判定方法
EP3059248A1 (en) 2008-05-09 2016-08-24 Abbvie Deutschland GmbH & Co. KG Antibodies to receptor of advanced glycation end products (rage) and uses thereof
WO2010096385A2 (en) * 2009-02-17 2010-08-26 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit Methods and compositions for the treatment of autoimmune disease
US9234037B2 (en) 2009-10-27 2016-01-12 Ucb Biopharma Sprl Method to generate antibodies to ion channels
US9383367B1 (en) 2010-12-07 2016-07-05 Chunli Liu Methods of detecting conjugation site-specific and hidden epitope/antigen
WO2013020557A1 (en) 2011-08-08 2013-02-14 Syddansk Universitet Method and antibodies for the identification of ubiquitinated proteins and sites of ubiquitination
MA41842A (fr) * 2015-03-31 2018-02-06 Oblique Therapeutics Ab Nouveaux procédés de sélection d'épitope

Also Published As

Publication number Publication date
CN109891247B (zh) 2022-10-04
GB201617002D0 (en) 2016-11-23
IL265612A (en) 2019-05-30
ES2994658T3 (en) 2025-01-28
MA46454A (fr) 2019-08-14
EP3523659A1 (en) 2019-08-14
KR20190062504A (ko) 2019-06-05
CN109891247A (zh) 2019-06-14
RU2019108573A3 (es) 2021-01-21
RU2019108573A (ru) 2020-11-06
CA3039064A1 (en) 2018-04-12
BR112019006624A2 (pt) 2019-07-02
WO2018065599A1 (en) 2018-04-12
US11408883B2 (en) 2022-08-09
US20200041499A1 (en) 2020-02-06
EP3523659C0 (en) 2024-08-14
KR102411384B1 (ko) 2022-06-20
NZ752437A (en) 2022-12-23
IL265612B1 (en) 2023-12-01
JP2020502482A (ja) 2020-01-23
EP3523659B1 (en) 2024-08-14
IL265612B2 (en) 2024-04-01
AU2017339096B2 (en) 2023-03-30
AU2017339096A1 (en) 2019-05-02
JP7046931B2 (ja) 2022-04-04

Similar Documents

Publication Publication Date Title
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
WO2018035084A8 (en) Monovalent asymmetric tandem fab bispecific antibodies
EP3954703A3 (en) Tri-specific binding molecules and methods of use thereof
MX376121B (es) Anticuerpos biespecíficos para pd1 y tim3.
MY195993A (en) Antibodies and Antibody Fragments for Site-Specific Conjugation
WO2015184001A8 (en) Anti-tnf-alpha glycoantibodies and uses thereof
HK1249124A1 (zh) 用於表位选择的新方法
AR105267A1 (es) Anticuerpos de unión a tau
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
PH12019500551A1 (en) Antibody specifically binding to il-17a and functional fragment thereof
PH12019502298A1 (en) Monoclonal antibody to pd-l1
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
MX2019003908A (es) Metodo por multiproteasa.
WO2013115410A3 (en) Anti-phospholipase d4 antibody
HK1220207A1 (zh) 人源化抗n2抗体
WO2020127354A3 (en) Polypeptides
CU24556B1 (es) Anticuerpos anti-basigin humanizados
MY197993A (en) Method for protein purification
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra